BIONEXUS GENE LAB CORP
BGLCNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $0.62 β $4.97
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 2.9M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $76,156
- P/E Ratio
- β
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-1.25
- Dividend Yield
- β
- Dilution (1yr)
- +3.3%
BIONEXUS GENE LAB CORP
BGLCAbout BIONEXUS GENE LAB CORP
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.